RhumbLine Advisers
ARCT icon

RhumbLine Advisers’s Arcturus Therapeutics ARCT Stock Holding History

RhumbLine Advisers’s Portfolio ARCT Stock Details ARCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$214K Buy
31,887
+1,011
+3% +$7.97K ﹤0.01% 3253
2026
Q1 		$238K Buy
30,876
+198
+0.6% +$1.45K ﹤0.01% 3039
2025
Q4 		$188K Sell
30,678
-9,064
-23% -$97.9K ﹤0.01% 3204
2025
Q3 		$732K Sell
39,742
-395
-1% -$6.34K ﹤0.01% 2437
2025
Q2 		$522K Buy
40,137
+6,636
+20% +$78.5K ﹤0.01% 2658
2025
Q1 		$355K Buy
33,501
+457
+1% +$7.25K ﹤0.01% 2793
2024
Q4 		$561K Buy
33,044
+47
+0.1% +$885 ﹤0.01% 2610
2024
Q3 		$766K Sell
32,997
-1,189
-3% -$25.4K ﹤0.01% 2410
2024
Q2 		$832K Sell
34,186
-3,382
-9% -$103K ﹤0.01% 2340
2024
Q1 		$1.27M Buy
37,568
+1,409
+4% +$49.9K ﹤0.01% 2126
2023
Q4 		$1.14M Sell
36,159
-278
-0.8% -$6.61K ﹤0.01% 2188
2023
Q3 		$931K Buy
36,437
+675
+2% +$20.8K ﹤0.01% 2251
2023
Q2 		$1.03M Buy
35,762
+5,363
+18% +$146K ﹤0.01% 2269
2023
Q1 		$729K Buy
30,399
+1,219
+4% +$21.9K ﹤0.01% 2269
2022
Q4 		$495K Buy
29,180
+915
+3% +$16K ﹤0.01% 2465
2022
Q3 		$419K Buy
28,265
+2,567
+10% +$43.1K ﹤0.01% 2574
2022
Q2 		$404K Sell
25,698
-1,229
-5% -$24.1K ﹤0.01% 2607
2022
Q1 		$726K Sell
26,927
-2,412
-8% -$61.6K ﹤0.01% 2268
2021
Q4 		$1.09M Sell
29,339
-303
-1% -$12.3K ﹤0.01% 2172
2021
Q3 		$1.42M Buy
29,642
+975
+3% +$43.7K ﹤0.01% 2069
2021
Q2 		$970K Buy
28,667
+7,287
+34% +$247K ﹤0.01% 2261
2021
Q1 		$883K Sell
21,380
-3,453
-14% -$206K ﹤0.01% 2237
2020
Q4 		$1.08M Buy
24,833
+7,969
+47% +$540K ﹤0.01% 2098
2020
Q3 		$723K Sell
16,864
-459
-3% -$22.8K ﹤0.01% 2121
2020
Q2 		$810K Buy
+17,323
New +$597K ﹤0.01% 2128

Other funds holding ARCT

Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

RhumbLine Advisers's ARCT Position: Q2 2026 in Review

RhumbLine Advisers increased its Arcturus Therapeutics (ARCT) stake by 3.3% in Q2 2026, buying an estimated $7.97K and bringing the position to 31,887 shares worth $214K. The position accounts for ﹤0.01% of the portfolio, ranked #3253.

RhumbLine Advisers first reported a position in ARCT in Q2 2020 and has held it in 25 quarters since. The position peaked at $1.42M in Q3 2021. 123 funds tracked by Wall St. Rank hold ARCT as of Q2 2026.

  • RhumbLine Advisers held 31,887 shares of Arcturus Therapeutics worth $214K as of Q2 2026.
  • RhumbLine Advisers bought 1,011 Arcturus Therapeutics shares in Q2 2026, an estimated $7.97K.
  • Arcturus Therapeutics made up ﹤0.01% of RhumbLine Advisers's portfolio in Q2 2026, its #3253 holding.
  • RhumbLine Advisers first reported a position in Arcturus Therapeutics in Q2 2020 and has held it in 25 quarters since.
  • RhumbLine Advisers's Arcturus Therapeutics position peaked at $1.42M in Q3 2021.
  • 123 funds tracked by Wall St. Rank held Arcturus Therapeutics as of Q2 2026.

Based on RhumbLine Advisers's 13F filing for Q2 2026, filed 12 Aug 2026.